Reviewing NovAccess Global (OTCMKTS:XSNX) & Liquidia (NASDAQ:LQDA)

NovAccess Global (OTCMKTS:XSNX) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Valuation & Earnings

This table compares NovAccess Global and Liquidia”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovAccess Global	N/A	N/A	-$2.66 million	($0.09)	0.00
Liquidia	$158.32 million	22.33	-$68.92 million	($0.83)	-48.34

NovAccess Global has higher earnings, but lower revenue than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than NovAccess Global, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

NovAccess Global has a beta of 2.25, suggesting that its share price is 125% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Insider and Institutional Ownership

64.5% of Liquidia shares are owned by institutional investors. 1.4% of NovAccess Global shares are owned by insiders. Comparatively, 26.5% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares NovAccess Global and Liquidia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NovAccess Global	N/A	N/A	N/A
Liquidia	-43.53%	-209.33%	-25.32%

Analyst Recommendations

This is a summary of current ratings and recommmendations for NovAccess Global and Liquidia, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovAccess Global	0	0	0	0	0.00
Liquidia	2	1	7	2	2.75

Liquidia has a consensus target price of $43.44, indicating a potential upside of 8.29%. Given Liquidia’s stronger consensus rating and higher possible upside, analysts clearly believe Liquidia is more favorable than NovAccess Global.

Summary

Liquidia beats NovAccess Global on 7 of the 13 factors compared between the two stocks.

About NovAccess Global

NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient’s immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.